{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:51:23Z","timestamp":1753890683725,"version":"3.41.2"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T00:00:00Z","timestamp":1664150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81873668, 82070908"],"award-info":[{"award-number":["81873668, 82070908"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7202153"],"award-info":[{"award-number":["7202153"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2018YFA0800801"],"award-info":[{"award-number":["2018YFA0800801"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>This study aimed to investigate the skeletal outcomes of patients with osteogenesis imperfecta (OI) who received bisphosphonate (BP) treatment and entered drug holiday after achieving an age- and sex-specific bone mineral density (BMD) reference.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with OI receiving BP treatment were enrolled when they entered drug holidays of BPs. The skeletal outcomes were evaluated in detail during the drug holiday, including BMD, X-ray of the bone, bone fracture incidence, and bone turnover biomarkers. The pathogenic mutations of OI were identified by next-generation sequencing and confirmed by Sanger sequencing.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 149 OI patients (127 juveniles and 22 adults) who entered drug holidays after nearly 4 years of BP treatment were included. Areal BMD at the lumbar spine increased from 0.934 \u00b1 0.151 to 0.990 \u00b1 0.142 g\/cm<jats:sup>2<\/jats:sup> and was stable in the second (1.029 \u00b1 0.176 g\/cm<jats:sup>2<\/jats:sup>) and third years (1.023 \u00b1 0.174 g\/cm<jats:sup>2<\/jats:sup>) of BP drug holidays, and BMD at the femoral neck, trochanter, and total hip had no significant change, but it was gradually inferior to that of the same-gender juveniles in the second and third years of the drug holiday. BMD at the lumbar spine and proximal hip did not change and was inferior to that of the same-gender adults. The average time of fractures fluctuated from 0.18 to 0.08 per year in juveniles, while only one adult suffered from a fracture during BP drug holidays. Bone turnover markers were in the normal range, except for a mildly high level of \u03b2-carboxy-terminal cross-linked telopeptide of type 1 collagen in the juvenile group. A total of 17 (11.4%) patients received BP retreatment because of bone loss during the drug holiday. OI type III and type IV and <jats:italic>COL1A2<\/jats:italic> mutation were correlated to a longer duration of BP treatment to enter drug holidays (all <jats:italic>p<\/jats:italic> &amp;lt; 0.05). Old age at initial treatment (OR, 1.056) and OI type III (OR, 10.880) were correlated to a higher risk of BP retreatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>OI patients will undergo nearly 4 years of BP treatment to achieve drug holidays. During the 3 years of the drug holiday, the patients\u2019 BMD is stable, and fracture incidence does not increase significantly. Patients are more inclined to need retreatment during drug holidays owing to the late start of BP treatment and more severe OI phenotypes.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2022.901925","type":"journal-article","created":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T08:43:27Z","timestamp":1664181807000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Skeletal outcomes of patients with osteogenesis imperfecta during drug holiday of bisphosphonates: a real-world study"],"prefix":"10.3389","volume":"13","author":[{"given":"Yongze","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunjie","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weibo","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoping","family":"Xing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"R95","DOI":"10.1530\/eje-20-0299","article-title":"Osteogenesis imperfecta: An update on clinical features and therapies","volume":"183","author":"Marom","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"17052","DOI":"10.1038\/nrdp.2017.52","article-title":"Osteogenesis imperfecta","volume":"3","author":"Marini","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s00439-021-02302-2","article-title":"Collagen transport and related pathways in osteogenesis imperfecta","volume":"140","author":"Claeys","year":"2021","journal-title":"Hum Genet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2020.109789","article-title":"Signaling pathways affected by mutations causing osteogenesis imperfecta","volume":"76","author":"Etich","year":"2020","journal-title":"Cell signal"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s11914-021-00665-z","article-title":"Osteogenesis imperfecta-who needs rodding surgery","volume":"19","author":"Fassier","year":"2021","journal-title":"Curr Osteoporos Rep"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1177\/1759720x20969262","article-title":"Management of primary and secondary osteoporosis in children","volume":"12","author":"Sakka","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-3745","article-title":"Bisphosphonate treatment and the characteristics of femoral fractures in children with osteogenesis imperfecta","volume":"102","author":"Vuorimies","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.4158\/ep151184.Or","article-title":"The clinical characteristics and efficacy of bisphosphonates in audlt patients with osteogenesis impergecta","volume":"22","author":"Xu","year":"2016","journal-title":"Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2019.06.011","article-title":"Effects of zoledronic acid on vertebral shape of children and adolescents with osteogenesis imperfecta","volume":"127","author":"Li","year":"2019","journal-title":"Bone"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2017.07.004","article-title":"Treatment with neridronate in children and adolescents with osteogenesis imperfecta: Data from open-label, not controlled, three-year Italian study","volume":"103","author":"Idolazzi","year":"2017","journal-title":"Bone"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1172\/jci15952","article-title":"The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta","volume":"110","author":"Rauch","year":"2002","journal-title":"J Clin Invest"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/bpo.0000000000000552","article-title":"Unusual femur stress fractures in children with osteogenesis imperfecta and intramedullary rods on long-term intravenous pamidronate therapy","volume":"36","author":"Hegazy","year":"2016","journal-title":"J Pediatr Orthop"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2805","article-title":"Recurrent proximal femur fractures in a teenager with osteogenesis imperfecta on continuous bisphosphonate therapy: Are we overtreating","volume":"31","author":"Vasanwala","year":"2016","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(13)61091-0","article-title":"Risedronate in children with osteogenesis imperfecta: A randomised, double-blind, placebo-controlled trial","volume":"382","author":"Bishop","year":"2013","journal-title":"Lancet (London England)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-017-4143-8","article-title":"Gene mutation spectrum and genotype-phenotype correlation in a cohort of Chinese osteogenesis imperfecta patients revealed by targeted next generation sequencing","volume":"28","author":"Liu","year":"2017","journal-title":"Osteoporos Int J established as result coop between Eur Found Osteoporos Natl Osteoporos Found USA"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0082098","article-title":"Bone mineral density of the spine in 11,898 Chinese infants and young children: A cross-sectional study","volume":"8","author":"Xu","year":"2013","journal-title":"PLoS One"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2010.12.013","article-title":"Normative data and percentile curves for dual energy X-ray absorptiometry in healthy Indian girls and boys aged 5-17 years","volume":"48","author":"Khadilkar","year":"2011","journal-title":"Bone"},{"key":"B18","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00198-013-2418-2","article-title":"Reference values of bone mineral density and prevalence of osteoporosis in Chinese adults","volume":"25","author":"Zhang","year":"2014","journal-title":"Osteoporos Int J established as result coop between Eur Found Osteoporos Natl Osteoporos Found USA"},{"key":"B19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.7326\/m19-0533","article-title":"Long-term drug therapy and drug discontinuations and holidays for osteoporosis fracture prevention: A systematic review","volume":"171","author":"Fink","year":"2019","journal-title":"Ann Internal Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2016.02.018","article-title":"Scoliosis in osteogenesis imperfecta caused by Col1a1\/Col1a2 mutations - genotype-phenotype correlations and effect of bisphosphonate treatment","volume":"86","author":"Sato","year":"2016","journal-title":"Bone"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0578-1310.2009.07.003","article-title":"Height and weight standardized growth charts for Chinese children and adolescents aged 0 to 18 years","volume":"47","author":"Li","year":"2009","journal-title":"Chin J Pediatr"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.16.2.101","article-title":"Genetic heterogeneity in osteogenesis imperfecta","volume":"16","author":"Sillence","year":"1979","journal-title":"J Med Genet"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnab017","article-title":"Osteogenesis imperfecta: Mechanisms and signaling pathways connecting classical and rare oi types","volume":"43","author":"Jovanovic","year":"2021","journal-title":"Endocr Rev"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-020-00707-1","article-title":"Bisphosphonate therapy and tooth development in children and adolescents with osteogenesis imperfecta","volume":"107","author":"Malmgren","year":"2020","journal-title":"Calcif Tissue Int"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s11914-018-0464-6","article-title":"Current understanding of epidemiology, pathophysiology, and management of atypical femur fractures","volume":"16","author":"Starr","year":"2018","journal-title":"Curr Osteoporos Rep"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4244","article-title":"Duration-dependent increase of human bone matrix mineralization in long-term bisphosphonate users with atypical femur fracture","volume":"36","author":"Farlay","year":"2021","journal-title":"J Bone miner Res Off J Am Soc Bone Miner Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005088.pub4","article-title":"Bisphosphonate therapy for osteogenesis imperfecta","volume":"10","author":"Dwan","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"B28","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1159\/000381713","article-title":"Efficacy and safety of bisphosphonate therapy in children with osteogenesis imperfecta: A systematic review","volume":"84","author":"Rijks","year":"2015","journal-title":"Horm Res Paediatr"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.081238","article-title":"Alendronate treatment of the brtl osteogenesis imperfecta mouse improves femoral geometry and load response before fracture but decreases predicted material properties and has detrimental effects on osteoblasts and bone formation","volume":"24","author":"Uveges","year":"2009","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2006.02.071","article-title":"Pamidronate does not adversely affect bone intrinsic material properties in children with osteogenesis imperfecta","volume":"39","author":"Weber","year":"2006","journal-title":"Bone"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s11832-011-0380-0","article-title":"Changing pattern of femoral fractures in osteogenesis imperfecta with prolonged use of bisphosphonates","volume":"6","author":"Nicolaou","year":"2012","journal-title":"J Child Orthop"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-046286","article-title":"Knowledge, attitude and practices regarding health self-management among patients with osteogenesis imperfecta in China: An online cross-sectional survey","volume":"11","author":"Lai","year":"2021","journal-title":"BMJ Open"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-2413","article-title":"Pamidronate in children and adolescents with osteogenesis imperfecta: Effect of treatment discontinuation","volume":"91","author":"Rauch","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"B34","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1515\/jpem.2008.21.1.63","article-title":"Cyclic pamidronate therapy in children with osteogenesis imperfecta: Results of treatment and follow-up after discontinuation","volume":"21","author":"Andiran","year":"2008","journal-title":"J Pediatr Endocrinol Metab JPEM"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2006.11.020","article-title":"Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta","volume":"40","author":"Rauch","year":"2007","journal-title":"Bone"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3833","article-title":"Osteogenesis imperfecta: Skeletal outcomes after bisphosphonate discontinuation at final height","volume":"34","author":"Robinson","year":"2019","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2019.07.003","article-title":"Bisphosphonate treatment changes regional distribution of trabecular microstructure in human lumbar vertebrae","volume":"127","author":"Vom Scheidt","year":"2019","journal-title":"Bone"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/s1297-319x(00)00240-2","article-title":"Bone status in primary hyperparathyroidism","volume":"68","author":"Chappard","year":"2001","journal-title":"Joint Bone Spine"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2019-00924","article-title":"Comparison of teriparatide and denosumab in patients switching from long-term bisphosphonate use","volume":"104","author":"Lyu","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2567","article-title":"Intravenous bisphosphonate therapy of young children with osteogenesis imperfecta: Skeletal findings during follow up throughout the growing years","volume":"30","author":"Palomo","year":"2015","journal-title":"J Bone miner Res Off J Am Soc Bone Miner Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-018-0307-y","article-title":"Longitudinal growth curves for children with classical osteogenesis imperfecta (Types iii and iv) caused by structural pathogenic variants in type I collagen","volume":"21","author":"Barber","year":"2019","journal-title":"Genet Med Off J Am Coll Med Genet"},{"key":"B42","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1080\/03008207.2021.1932853","article-title":"Clinical, genetic characteristics and treatment outcomes of children and adolescents with osteogenesis imperfecta: A two-center experience","volume":"63","author":"Erba\u015f","year":"2021","journal-title":"Connect Tissue Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1097\/mjt.0000000000000236","article-title":"Efficacy of bisphosphonates on bone mineral density and fracture rate in patients with osteogenesis imperfecta: A systematic review and meta-analysis","volume":"23","author":"Shi","year":"2016","journal-title":"Am J Ther"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.c.31532","article-title":"Pharmacological and biological therapeutic strategies for osteogenesis imperfecta","volume":"172","author":"Marom","year":"2016","journal-title":"Am J Med Genet Part C Semin Med Genet"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.901925\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T08:43:31Z","timestamp":1664181811000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.901925\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,26]]},"references-count":44,"alternative-id":["10.3389\/fendo.2022.901925"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.901925","relation":{},"ISSN":["1664-2392"],"issn-type":[{"type":"electronic","value":"1664-2392"}],"subject":[],"published":{"date-parts":[[2022,9,26]]},"article-number":"901925"}}